CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, while the CD34+CD38−/dim phenotype with aberrant marker expression (e.g., CD45RA, CD123, or CD26) is well-documented in CML and acute myeloid leukemia, a definitive LSC phenotype for lymphoid leukemia remains undefined.